Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn's Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa

This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn's disease (CD) patients. 106 CD patients were undergoing treatment with IFX from five hospitals in Shanghai, China. Clinical remission to IFX induction therapy was defined as Crohn's disease activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Lijuan, Yang, Xuehua, Xia, Lu, Zhong, Jie, Ge, Wensong, Wu, Jianxin, Liu, Hongchun, Liu, Fei, Liu, Zhanju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383520/
https://www.ncbi.nlm.nih.gov/pubmed/25873771
http://dx.doi.org/10.1155/2015/793764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383520/
https://www.ncbi.nlm.nih.gov/pubmed/25873771
http://dx.doi.org/10.1155/2015/793764

Ejemplares similares